title: Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
abstract: In the past 5 years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis factor receptor superfamily, represents a promising target for enhancing antitumor immune responses. CD137 helps regulate the activation of many immune cells, including CD4(+) T cells, CD8(+) T cells, dendritic cells, and natural killer cells. Recent studies indicate that the antitumor efficacy of therapeutic tumor-targeting antibodies can be augmented by the addition of agonistic antibodies targeting CD137. As ligation of CD137 provides a costimulatory signal in multiple immune cell subsets, combination therapy of CD137 antibody with therapeutic antibodies and/or vaccination has the potential to improve cancer treatment. Recently, clinical trials of combination therapies with agonistic anti-CD137 mAbs have been launched. In this review, we discuss the recent advances and clinical promise of agonistic anti-CD137 monoclonal antibody therapy.
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University, Stanford, California. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yonezawa
authors.affiliation: Immunology and Rheumatology, Stanford University, Stanford, California.
authors.forename: Suparna
authors.initials: S
authors.lastname: Dutt
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University, Stanford, California. Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, California.
authors.forename: Cariad
authors.initials: C
authors.lastname: Chester
authors.affiliation: Transgenic, Knockout and Tumor Model Center, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, California.
authors.forename: Jeewon
authors.initials: J
authors.lastname: Kim
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University, Stanford, California. kohrt@stanford.edu.
authors.forename: Holbrook E
authors.initials: HE
authors.lastname: Kohrt
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9